Quantitative viral outgrowth assays (QVOA) use limiting dilutions of CD4 + T cells to measure the size of the latent HIV-1 reservoir, a major obstacle to curing HIV-1. Efforts to reduce the reservoir require assays that can reliably quantify its size in blood and tissues. Although QVOA is regarded as a "gold standard" for reservoir measurement,
Introduction

1
The latent HIV-1 reservoir that persists following treatment with suppressive ART 2 exists primarily in resting CD4 + T cells and is an obstacle to eradicating HIV-1 [1] [2] [3] [4] .
3
There are substantial ongoing efforts to eliminate or reduce the size of this 4 reservoir [5] [6] [7] . Evaluating such efforts requires assays that can reliably quantify its size 5 in blood and tissues in order to monitor its changes during curative intervention detected by an assay for either p24 antigen or HIV RNA in the supernatant of these
12
T cells, 2) each assay takes weeks to complete and is expensive (∼$3,000), 3) substantial 26 personnel time is required for cell purification, culture and monitoring supernatants for 27 HIV replication, limiting test throughput to two to four QVOAs per lab per week, 4) 28 not all replication-competent virus is detected by a single QVOA [11] , and 5) different 29 laboratories employ varying methods [8] .
30
In addition, the performance characteristics of QVOAs performed within and 31 between labs have not been carefully evaluated, a gap that this study was designed to addition, the number of infectious units in positive wells is not known, which also adds 36 to the assays' variability. We describe in the next section Markov-chain Monte Carlo
37
(MCMC) methods that we developed to account for these inevitable background sources 38 of variation while estimating additional variation, including batch effects and inter-lab 39 variation, as well as assessing the impact of freezing PBMC samples on assay 40 performance. We also describe simulations to validate these methods and to assess the 41 implications of the parameter estimates. We then present the results of our Participants in the RAVEN project are enrolled and followed as part of the UCSF
48
OPTIONS and SCOPE programs, with specific consent for apheresis collections and 49 testing for this study as approved by the UCSF Committee on Human Research (IRB) 50 # 10-03244.
51
Experimental design
52
The five ART-suppressed HIV-1 infected participants for the current study were 53 selected to have diverse replication-competent reservoirs based on QVOA results from a 54 previously published study [10] . Leukapheresis uniquely coded liquid nitrogen-cryopreserved PBMC aliquots that were distributed to 65 all four labs for testing 4 -12 months after freezing, depending on lab testing capacity. 66 Aliquots were blinded as to participant and aliquot identity, except that all labs had 67 knowledge that the negative control was not included in the fresh panel. Within each 68 lab, the frozen panel was analyzed in balanced batches of two aliquots each, designed to 69 enable measurement of both within-batch and between-batch variation ( Figure 1 ).
70
Labs thawed aliquots (if frozen), isolated CD4
+ T cells (CD4s), and performed
71
QVOA per lab protocol (S2 Table) . S3 Table provides + participant was studied fresh and was not batched with any other aliquots. Frozen panel (nine batches): Three aliquots from each participant were cryopreserved and batched together with one other aliquot. Five batches contain two aliquots from the same HIV + participant. Two HIV + participants are chosen to supply one aliquot to the same batch (here, participants 2 and 3). The remaining three batches contain an aliquot from one of the remaining HIV + participants and an aliquot from the negative control. In each lab, different HIV + participants are chosen for the mixed batch (see S1 Table for complete experimental design). and the lab where the assay was performed (l = 1 . . . 4, referring to U. Pitt., UCSD,
108
JHU, and SR, respectively). Viral outgrowth was assumed to follow a Poisson model, in 109 which a well containing n input cells has independent probability of being positive equal 110 to
where V ijkl is the probability that a single cell in the well is capable of causing 112 outgrowth,
113
PLOS
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In this expression, S ij is set to one if aliquot j from participant i was cryopreserved 114 before the assay, and otherwise is set to zero. Each other term represents a fixed or 115 random effect (Table 1) . 
In this framework, σ a quantifies extra variation that is distinct for each single provided by our data, we aimed to use prior distribution assumptions for the 153 parameters that were "weak." To make our assumptions neutral about the existence of 154 nonzero random effects, we fit model versions with and without each of σ a , σ b , and σ c , 155 with equal prior probability for each.
156
A uniform or normal distribution was used as prior for each fixed-effect parameter, 157 and a half-Cauchy prior was used for each random effect parameter:
where Cauchy scale parameters τ = 1, 2, 3, 4 were tried.
159
Eight versions of the model were fitted, one for each combination of the three 160 random effects listed in Table 1 . These were all given equal prior probability, making 161 the effective prior for each random effect an equal mixture of the half-Cauchy noted 162 above and a point mass at zero. Posterior distributions for parameters were estimated 163 using PyStan 2.12 [16] , with four parallel chains of 2500 iterations each. The first half of 164 each chain was discarded as warmup. A posterior probability for each model was 165 calculated using the Watanabe-Akaike Information Criterion (WAIC) [17] . Complete 166 model specifications in Stan are provided (S1 Appendix).
167
A set of 1000 independent samples from each of the eight models' posterior 
192
In the scenario with no variation, each well is positive with probability sampled as in the normal formulation, and each well is positive with probability
a , representing the probability that a negative binomial 200 random variable is positive when it has mean n exp (v i + b kl ) and dispersion parameter 201 σ 2 a .
202
For multi-lab simulations including both fresh and cryopreserved samples, the full 203 experiment as specified in S3 Table was simulated, using ensemble posterior median 204 parameter estimates reported in S8 Table ("All four labs, using JHU day 21 readout"). 205 Random effects and the probability that each well is positive followed the model 206 described above ("Statistical model"). In addition, to compute the probability that the 207 method may overestimate σ a , σ b , or σ c despite the true parameter value equaling zero, 208 we repeated the simulations three times, each time replacing one of these three 209 parameters with zero. We then reported the average probability of overestimation 210 among these simulations. 
Characterizing accuracy of assays
217
Simulations were used to illustrate the typical accuracy of each lab's assay in the absence 218 of batch effects (assuming that these could be rendered irrelevant by assaying specimens 219 from the same person -such as baseline and post-treatment -in the same batch). For 220 each of 1000 samples from the batch effect-free ensemble posterior (see above,
221
"Markov-chain Monte Carlo estimation") and each assumed true IUPM, 1000 simulations 222 of well-by-well output were performed for each assay. For each simulation, aliquot-level 223 random effects a ij were sampled from N (0, σ a ), and lab-level random effects c il were 224 either sampled from N (0, σ c ), sampled from N 0, √ 2 × σ c , or set to zero (choice of 225 distribution described below). In each simulation, the maximum likelihood estimate of 226 IUPM was compared to the true IUPM (scaled by lab-specific factor β l ) to obtain the 227 log 10 -error. The median of absolute log 10 -error was then recorded for each of the 1000 228 samples from the ensemble posterior. For each lab's assay, we then report the median, 229 2.5%ile, and 97.5%ile of these median absolute errors across the posterior sample.
230
We ran two versions of these simulations. For the first version, we supposed that 231 each assay has equal claim to biological truth and that lab-based random effects c il are 232 discrepancies from a consensus standard. These random effects were drawn from 233 N (0, σ c ), where σ c is the estimated value drawn from the ensemble posterior. For the 234 second version, we chose the JHU assay (index l = 3) to represent the standard against 235 which other assays are measured. Under this assumption, the differences c il − c i,3 are 236 lab l's discrepancies from the standard. To simulate data in which the c il themselves are 237 the discrepancies, we sampled these random effects from N 0, √ 2 × σ c for all l = 3.
238
All c i,3 were set to zero.
239
The same simulations were also used to compare accuracy between each pair of 240 assays. For each assumed true IUPM and ensemble posterior sample, the difference in 241 median absolute log 10 -error between two assays was recorded for the 1000 matched 242 simulations. For each pair of assays, we report the median, 2.5%ile, and 97.5%ile of 243 these differences across the posterior sample.
244
At JHU and SR, the number of replicate wells with one million cells apiece varied
245
with the number of rCD4s purified from each aliquot. First, to mimic typical aliquots, 246 we simulated the JHU assay with 26 replicates and the SR assay with 12 replicates.
247
Second, to consider the situation where JHU and SR used a number of cells similar to 248 those used by U. Pitt. and UCSD, we simulated both assays with 8 replicates.
249
Simulation of clinical trial 250
Latency-reducing treatment was simulated to illustrate the power and accuracy of
251
QVOA for measuring changes in IUPM. Pretreatment log 10 IUPM from each participant 252 was assumed to follow a normal distribution with mean −0.013 and standard deviation 253 0.675, consistent with the cohort studied in [10] . Within-person change in log 10 IUPM 254 from pre-to post-treatment was normally distributed with mean δ and standard 255 deviation σ δ . In control participants, "pre" and "post" IUPMs were equal. Both JHU 256 and UCSD assay protocols were simulated, using ensemble posterior median parameter 257 estimates reported in S8 Table ( "All four labs, using JHU day 21 readout"). For the
258
JHU assay, we simulated 50 million-cell wells for fresh samples, 26 million-cell wells for 259 frozen samples, and two wells of each other size (five-fold dilution from 200,000 to 320). 260 The UCSD assay was simulated according to the configuration in S3 Table. 261
Both batched and unbatched analyses were studied. In batched analysis, all samples 262 were treated as cryopreserved, and only aliquot-and lab-level excess variation were 263 included (all batch effects b kl = 0). In unbatched analysis, all samples were treated as 264 fresh, and all three levels of excess variation were included. In both cases, the same 265 lab-level random effect c il was assumed to hold for both samples from each participant. 266 For each sample, the maximum likelihood IUPM was estimated, with negative assay 267 results replaced with a value equal to one-half of the minimum possible positive assay 268 value. A before-after change in log 10 IUPM was calculated for each individual from 269 these IUPM estimates.
270
Two treatment effects were studied: a 10-fold median reduction in IUPM (strong 271 effect), but with substantial person-to-person variation (δ = −1, σ δ = 0.5), and a weak 272 effect with lower person-to-person variation (δ = −log 10 (3) ≈ −0.48, σ δ = 0.16). We 273 intended the strong effect to represent a treatment with clinical potential, and we 274 simulated an early, discovery-oriented study with 6 treated participants and no controls, 275 analyzed by a paired t-test. We intended the weak effect to represent a treatment with 276 minor improvement over those currently reported [18] batches may help to reduce this error. Overall, the HC (0, 1) prior slightly outperformed 319 the other three priors tested (S5 Table, S6 Table, S7 Table) , and so it was chosen for all 320 analysis of experimental data.
321
To investigate whether MCMC might lead us to conclude falsely that variation is 322 present at a given level, we simulated data for which one or more of the three sources of 323 variation was removed. When all three sources were removed from simulations, MCMC 324 rarely produced estimates surpassing the level of variation observed in the experimental 325 data (posterior probability weight typically no more than 0.1%, bottom row of Table 3 ). 326 When one or two sources of variation were included, MCMC often misidentified the 327 source of variation, though misidentification as aliquot-level variation was less common 328 and typically produced estimates smaller than the experimental estimate. Even when 329 one source was misidentified as another, estimates of total variation coming from all 330 three levels performed well.
331 Table 2 . Performance of MCMC estimation, using the ensemble model and HC (0, 1) prior, in simulation of multi-lab experimental design in S3 Table 3 . Performance of MCMC estimation assuming a true random effect parameter of zero, using HC (0, 1) prior, in multi-lab simulation.
Condition
Probability of misidentifying source of variation (median and 95% CI)
Performance of total variation estimate
Source Posterior prob. assigned to parameter > 0 Posterior prob. assigned to parameter ≥ median estimate in Table 5 Median Although the goal of each lab's assay is the same -to quantify infectious provirus 334 infecting resting CD4+ T cells -infection levels reported by UCSD were consistently 335 higher than those reported by the other three labs (Figure 2 Table) , and it might also reflect a systematically lower
354
IUPM scale (half that of JHU, although credible intervals overlap). In addition to this systematic lab effect, we determined that random variation in 356 excess of the baseline Poisson-binomial model was likely (posterior probability 85%) at 357 all three levels -between-aliquot, between-batch, and between-lab. Excess variation in 358 at least one level was a near-certainty (posterior probability = 1 − 10 −22 ). Table 5 359 summarizes estimates of excess variation at each level. As study design was limited to 360 batches of only one or two aliquots, it is not easy to disentangle variation at the aliquot 361 and batch levels; estimates are inversely correlated with one another (slope −0.69, S1 Running MCMC analysis on each lab separately suggested that each lab's assay offered 381 a similar level of precision. The median estimates for aliquot-and batch-level variation 382 for each lab fell within the 95% credible interval of the joint estimates in Table 5 , and 383 none were more than 21% away from the corresponding median estimate (S8 Table, 
391
Neglecting the strong evidence supporting excess random variation at multiple levels 392 (Table 5) can generate misleading interpretations about precision of lab procedures. To 393 demonstrate the relevance of accounting for excess random variation, we recomputed all 394 estimates in a model excluding this excess variation (Tables 4 and 6 , right column).
395
While median estimates did not change greatly, credible intervals shrank by 2-to 10-fold 396 for each parameter. Neglecting this excess variation therefore overstates certainty in 397 parameter estimates. One particular effect of this error in our experiment would be to 398 conclude, rather strongly (p < 0.001), that cryopreservation increases observed infection 399 frequencies in the JHU lab.
400
Paying close attention to the sources of random and systematic variation can help in 401 choosing assays for and optimizing design of clinical trials for latency-reducing therapies. 402 In the next two sections, we demonstrate how simulations based on the parameter 403 estimates described above may guide this effort.
404
Simulations based on experimental outcomes can be used to 405 compare assay accuracy
406
While each lab's assay aims to measure the replication-competent HIV latent reservoir, 407 protocols differ among them: U. Pitt., JHU, and SR use a p24 antigen test to detect 408 viral outgrowth, while UCSD uses an RNA PCR test; U. Pitt., JHU, and SR use PHA 409 and gamma-irradiated PBMCs to stimulate resting cells, while UCSD uses antibody to 410 CD3/CD28 bound to the culture plate (S2 Table) . Additionally, target cells added to 411 propagate virus differs among labs. These protocol differences may explain both 412 systematic and random variation between labs (Tables 4, 5 ). We may think of these labs 413 as measuring different aspects of latency, each with a valid claim to being a meaningful 414 measure, with experimental and biological motivations for specific protocol choices.
415
In the absence of an external standard defining latent reservoir size, we can 416 nonetheless address how sensitivity of an assay affects its accuracy. Specifically, assays 417 that use more input cells overall or have systematically high IUPMs (high fold-change in 418 Table 4 ) will have improved sensitivity. By drawing from the joint posterior distribution 419 (S9 Table) and simulating data for each draw, we investigated how sensitivity relates to 420 the accuracy of measuring small reservoirs (see Methods).
421
For typical infection frequencies (1 IUPM on the U. Pitt. scale, higher or lower for 422 the other assays according to systematic effect, Table 4 Table 4 ), for a majority of parameter draws, a majority of simulated assay outcomes are 428 all-negative, resulting in infinite error on the log scale. In the case of UCSD and JHU, 429 improved accuracy has costs: The more sensitive RNA-based assay used by UCSD may 430 have a higher false positive rate (2 of 18 control wells with one million cells were Accuracy of assays used in the experimental study. Each assay is measured against a consensus standard, appropriately scaled by β l for that assay. "All-negative" represents infinite error on the log scale, which occurs when the maximum likelihood estimate of IUPM is zero.
If false positives did in fact occur in HIV + samples studied by the UCSD RNA-based 438 assay, it would be reflected in our estimates as both improved sensitivity for UCSD 439 (higher β 2 ) and reduced correlation between labs (higher σ c ). We used simulations to 440 investigate the possible tradeoff between sensitivity and specificity, treating the JHU 441 assay as a gold standard (not subject to lab-based random effect) and subjecting UCSD 442 to the total between-lab variation (applying a random effect with standard deviation performance against a consensus standard (applying σ c equally to both assays, S10
454 Table and S11 Table) or against a chosen standard assay (applying √ 2 × σ c to other 455 assays, S12 Table and S13 Table) . Other assay is all-negative Fig 4 . Difference in accuracy between UCSD and JHU assays, assuming that the JHU assay is a gold standard (not subject to lab-based random effect). Batch variation-free ensemble estimates of parameters were used in simulations. Median estimate and 95% credible intervals shown for 0.1, 0.2, 0.5, 1, and 2 IUPM on the U. Pitt. scale. All values plotted are also provided in S12 Table and S13 Table. Batched study design can improve power to detect latency Table) , we supposed that roughly 468 half as many cells would be recovered from cryopreservation as would be available fresh. 469 For the weaker therapy, batching substantially improved power to detect and 470 accuracy to measure latency reduction following treatment (Table 7) . Improvement was 471 greater for the UCSD protocol, with power increasing from 58.6% to 82.6% and median 472 absolute error declining from 0.14 log 10 to 0.10 log 10 . Although freezing-thawing 473 sacrificed half of the resting cells available to the JHU protocol, the benefits of batching 474 overcame this deficit, leading to a 15 percentage-point increase in study power.
475
For the stronger therapy studied in a smaller cohort, batching provided a modest 476 benefit to the UCSD protocol, but reduced cell availability in the JHU protocol 477 eliminated this benefit completely. Moreover, both protocols underestimated the effect 478 of treatment (−7% to −34% bias (Table 7) . This outcome resulted from our use of an 479
imputed IUPM in the case of negative assay results, a common practice in the field [19] . 480 Strong therapy that reduces latency 10-fold can often result in true IUPMs well below 481 the imputed value. In the batched JHU protocol, 35% of samples returned a negative 482 assay, leading to the largest underestimate of treatment effect. To provide an 483 alternative to the t-test that avoided imputation, a maximum likelihood estimate of 484 effect size was also computed. When this method was used, batching improved both 485 power and accuracy in all cases, but the resulting confidence intervals had poorer 486 coverage (S14 Table) . Maximum likelihood estimation underperformed MCMC
487
488
None of the three software packages that we tried produced fully satisfactory results
489
when applied to the experimental data. The best log-likelihood obtained was from a 490 model in Stata that excluded between-lab variation. When this variation was included, 491 the log-likelihood closely approached that of the best model before ending with an error. 492 In SAS, the model fitting completed for essentially the same model, with σ c = 0, but 493 with most parameters having standard errors equal to zero. In R, the model converged 494 to substantially different parameter values, with a much worse log-likelihood.
495
Aside from the lack of between-lab variation, which may reflect the bias toward zero 496 seen in single-lab simulations (see "Simulation validates MCMC method," above), many 497 results by maximum likelihood were similar to the MCMC results given above. The 498 cryopreservation effect and systematic lab effects were all within 10% of MCMC 499 posterior medians. The typical between-aliquot excess variation was estimated to be 500 1.61-fold (vs 1.50-fold by MCMC), with a p-value of 0.0003. The typical between-batch 501 excess variation was estimated to be 1.43-fold (vs 1.77-fold by MCMC), with p = 0.098. 502 A likelihood ratio test for at least one source of excess variation had p = 1.4 × 10 −13 . IUPM by a factor of 1.6 to 1.9 up or down ( Figure 3 , typical log 10 difference of 0.20 to 511 0.28). At lower true IUPMs, some assays had much larger median errors, while others 512 avoided major increases by use of a large number of input cells (JHU assay) or by use of 513 a readout that was more often positive (UCSD assay).
514
We found that the four assays appeared to differ from each other both systematically 515 (in scale; see Table 4 ) and randomly (between-lab variation in Table 5 ). These 516 differences may reflect the differing subsets of infectious units (IU) that the assays 517 detect. Recent work suggests that QVOAs detect only a fraction of the IU present in a 518 sample [11] . The assays' different stimulation and detection procedures likely cause each 519 to measure a different subset of IU. Different inducers of T cell activation have variable 520 effectiveness. In one study, the use of antibodies to CD3 and CD28 was more effective 521 than other methods [20] . For the detection step, HIV RNA by PCR is more sensitive 522 than digital ELISA assays for p24 antigen (e.g., Simoa [21] ), which in turn is more 523 sensitive than the standard ELISA assay for p24 antigen. Details of CD4 cell separation 524 and aspects of cell co-culture details like cell type and medium could also create 525 variability between labs. Measuring a larger subset of IU is desirable, because sampling 526 variation is relatively smaller when counts are higher, reducing relative error. A caveat, 527 however, is that the fraction of the total latent reservoir within a smaller subset could, 528 at least in principle, be more stable within and between individuals than that within a 529 larger subset. We could not assess this possibility, because we had no gold standard 530 measurement of the entire reservoir. In addition, higher readings that are due to false 531 positive wells will not improve measurement. The UCSD assay, which used an in-house 532 RT-PCR assay to detect HIV RNA rather than p24 antigen in culture supernatants, 533 had two false positive wells among 126 wells evaluated for an HIV-uninfected donor.
534
These were contiguous wells with one million cells each within a single one of three split 535 samples. This may have been due to contamination during culture supernatant testing 536 by RT-PCR, and in any case would not be a high enough rate to account for much of 537 the UCSD scale factor. differing effects for different people, and this variation may be as large or larger than 547 the variation due to measurement error. Unfortunately, the variation in intervention 548 effects may be difficult to accurately anticipate at the planning stage of a study [22] .
549
Another implication is the need to use designs that will not be biased by 550 regression-to-the-mean phenomena. For example, it might seem reasonable to exclude 551 from an intervention study potential participants who have QVOA results that are all 552 negative (measured IUPM = 0) at baseline, because they cannot go any lower. This 553 exclusion, however, will tend to cause the remaining participants to average lower on 554 repeat testing than at baseline, because the remaining subset has been depleted of some 555 downward measurement errors by the exclusion, while the repeat testing will include an 556 unbiased array of measurement errors. Therefore, a randomized parallel design should 557 be used if such a baseline exclusion is applied; treated and control arms will then have 558 comparable regression to the mean, resulting in a fair assessment of the intervention 559 effect.
560
We found evidence that controlled-rate freezing and liquid nitrogen storage and 561 shipping of PBMC did not cause substantial differences in QVOA results compared to 562 use of fresh cells. This is encouraging because of the practical difficulties in using fresh 563 cells and because storage enables assaying multiple specimens from the same person in 564 the same batch, eliminating batch variation from estimates of within-person changes. It 565 also permits clinical trials to be more readily conducted in trial sites without local 566 laboratories qualified to perform reservoir assays. Our simulations showed the potential 567 for gains in power and precision from such batching. There are, however, some 568 important caveats regarding storage. We had only 15 results on fresh cells, with no split 569 samples evaluated at the same lab. Despite this, our CI's were narrow enough to 570 provide good evidence against any systematic change due to storage of 2-fold or more 571 (Table 6 ). In addition, the lack of split fresh samples precluded effective evaluation of 572 the effect of storage on measurement variability. We also did not evaluate the effect of 573 storage duration. The SR assay was performed later, after longer storage, than the 574 other assays, and it also tended to have the lowest IUPMs. Using similar protocols to 575 the JHU assay, it also obtained lower numbers of input cells, and JHU obtained lower 576 input from stored samples than from the fresh samples collected at the same time.
577
Consequently, until additonal studies on impact of duration of storage on QVOA
578
IUPMs are conducted, we recommend that serial PBMC samples from participants in 579 intervention studies be frozen and batch tested as soon a practical following collection. 580 Our statistical methods and results indicate potential value for additional statistical 581 research on how to estimate and analyze QVOA data (and data from similar limiting 582 dilution assays). We found a 98% posterior probability of extra-Poisson variation 583 between split samples in the same batch at the same lab ( match those in the experimental study, except "JHU (8M)" and "SR (8M)," which use 637 fewer wells to match the cell input count of U. Pitt. and UCSD assays. UCSD. Each assay is measured against a consensus standard, appropriately scaled by 658 β l for that assay. "All-negative" on the y-axis represents infinite error on the log scale, 659 which occurs when the maximum likelihood estimate of IUPM is zero. 
